Genocea Biosciences Inc. (NASDAQ:GNCA) shares were down 1.5% during mid-day trading on Thursday . The company traded as low as $5.15 and last traded at $5.19, with a volume of 61,577 shares changing hands. The stock had previously closed at $5.27.

A number of research analysts have issued reports on GNCA shares. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a report on Monday, August 8th. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Genocea Biosciences currently has a consensus rating of “Buy” and a consensus target price of $17.95.

The stock’s 50-day moving average price is $4.60 and its 200-day moving average price is $4.48. The firm’s market capitalization is $141.67 million.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. Equities analysts predict that Genocea Biosciences Inc. will post ($1.63) EPS for the current fiscal year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.